State of the art in Empaglifozin in cardiovascular outcomes.

Back

ESC Premium Access

State of the art in Empaglifozin in cardiovascular outcomes.

Session: A perspective on the effects of Empaglifozin in cardiovascular outcomes

Topic: Drug therapy

Speaker: Doctor D. Fitchett (Toronto, CA)

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Doctor David Fitchett

St. Michael's Hospital, Toronto (Canada)

18 presentations

0 follower

4 more presentations in this session

Effect of empagliflozin on heart failure outcomes in subgroups by age: results from EMPA-REG OUTCOME

Speaker: Doctor P. Monteiro (Coimbra, PT)

Cardiovascular outcomes according to LDL cholesterol levels in EMPA-REG OUTCOME

Speaker: Doctor G. Langslet (Oslo, NO)

Effect of empagliflozin on cardiovascular death in subgroups by age: results from EMPA-REG OUTCOME

Speaker: Professor D. Fitchett (Toronto, CA)

Future direction for research in Empaglifozinon heart failure treatment.

Speaker: Associate Professor P. Sarafidis (Thessaloniki, GR)

Access

Slides

Video

Access the full session

A perspective on the effects of Empaglifozin in cardiovascular outcomes

Speakers: Doctor D. Fitchett, Doctor P. Monteiro, Doctor G. Langslet, Professor D. Fitchett, Associate Professor P. Sarafidis

Access

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources